| First Author | Zhang X | Year | 2023 |
| Journal | Carcinogenesis | Volume | 44 |
| Issue | 3 | Pages | 197-208 |
| PubMed ID | 36882165 | Mgi Jnum | J:336127 |
| Mgi Id | MGI:7486402 | Doi | 10.1093/carcin/bgad011 |
| Citation | Zhang X, et al. (2023) ARID1A mutations in cancer development: mechanism and therapy. Carcinogenesis 44(3):197-208 |
| abstractText | AT-Rich Interaction Domain 1A (ARID1A) is an important SWItch/Sucrose Non-Fermentation (SWI/SNF) chromatin remodeling complex subunit, and its coding gene has a high mutation frequency in many cancers. Current studies have reported that ARID1A mutational status is correlated to cancer development, including cell proliferation, invasiveness, metastasis, and morphological alterations. ARID1A acts as a tumor suppressor, regulating gene transcription, participating in DNA damage response, and influencing tumor immune microenvironment and signaling pathways. The absence of ARID1A in cancer can lead to widespread dysregulation of gene expression in cancer initiation, promotion, and progression. For patients with ARID1A mutations, effective individualized treatment can improve the prognosis of patients. In this review, we aim to discuss the mechanism of ARID1A mutations in cancer development and explore the significance of discoveries for treatment. |
